DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Breast Cancer

Interventions: Drug: DS-1103a
Drug: T-DXd

First Posted Date: 2023-03-13

Last Posted Date: 2024-04-30

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 78

Registration Number: NCT05765851

Locations: 🇫🇷
Oncopole - Institut Claudius Regaud, Toulouse cedex 9, Haute Garonne, France
🇨🇦
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 5 locations

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Phase 1

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: DS-7011a
Drug: Placebo

First Posted Date: 2022-12-06

Last Posted Date: 2024-10-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 26

Registration Number: NCT05638802

Locations: 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸
Oakland Hills Dermatology, Auburn Hills, Michigan, United States
🇺🇸
MediSearch Clinical Trials, Saint Joseph, Missouri, United States

and more 9 locations

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Phase 1

Completed

Conditions: Netherton Syndrome

Interventions: Drug: Placebo
Drug: DS-2325a

First Posted Date: 2022-10-18

Last Posted Date: 2023-05-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT05583669

Locations: 🇺🇸
Quotient Sciences -Miami, Miami, Florida, United States

A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Phase 2

Completed

Conditions: Pseudoxanthoma Elasticum

Interventions: Drug: DS-1211b
Other: Placebo

First Posted Date: 2022-10-06

Last Posted Date: 2024-11-13

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 64

Registration Number: NCT05569252

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇺🇸
Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States
🇺🇸
Boston Neuro Research Center, North Dartmouth, Massachusetts, United States

and more 4 locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Phase 3

Recruiting

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2022-09-27

Last Posted Date: 2024-11-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1170

Registration Number: NCT05555732

Locations: 🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States
🇯🇵
Osaka International Cancer Institute, Osaka, Japan
🇺🇸
Southern Cancer Center Pc, Daphne, Alabama, United States

and more 206 locations

A Dose Finding Study of VN-0200

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: VN-0200

First Posted Date: 2022-09-21

Last Posted Date: 2024-02-29

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 342

Registration Number: NCT05547087

Locations: 🇯🇵
SOUSEIKAI PS Clinic, Hakata, Fukuoka, Japan
🇯🇵
SOUSEIKAI Sumida Hopital, Sumida, Tokyo, Japan
🇯🇵
SOUSEIKAI Nishi-Kumamoto Hospital, Kumamoto, Japan

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Completed

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Trastuzumab deruxtecan

First Posted Date: 2022-07-14

Last Posted Date: 2024-03-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 256

Registration Number: NCT05458401

Locations: 🇮🇹
Institute Oncology Veneto, Padua, Italy
🇮🇹
Fondazione Policlinico Univeritario Agostino Gemeli, Rome, Italy
🇪🇸
Hospital Clínico San Carlos, Madrid, Spain

and more 18 locations

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Phase 4

Recruiting

Conditions: COPD Exacerbation Acute

Interventions: Drug: Sitafloxacin
Drug: Moxifloxacin Hydrochloride

First Posted Date: 2022-06-01

Last Posted Date: 2024-04-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 268

Registration Number: NCT05400369

Locations: 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, China

and more 15 locations

A Study of DS-9606a in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Cancer
Metastatic Cancer
Ovarian Cancer
Germ Cell Tumor

Interventions: Drug: DS-9606a

First Posted Date: 2022-05-27

Last Posted Date: 2024-07-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 85

Registration Number: NCT05394675

Locations: 🇺🇸
Florida Cancer Specialists & Research Institute, LLC, Sarasota, Florida, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States

and more 4 locations

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Phase 1

Completed

Conditions: Netherton Syndrome

Interventions: Drug: Placebo
Drug: DS-2325a

First Posted Date: 2022-05-24

Last Posted Date: 2023-03-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 64

Registration Number: NCT05388903

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy